Table 1.

Demographics and clinical characteristics of all patients.

			Anti-AChR		Duration				Previous
No.	Age (years)	Gender	Ab (nmol/L)	Onset	(months)	MGFA class	QMGS	Thymus status	therapies
1	64	M	−0.26	LO	18	I	3	None	PB
2	56	M	2.05	LO	4	I	3	None	None
3	25	F	0.7	EO	240	I	3	None	None
4	47	F	6.34	EO	2	IIB	11	Thymoma	None
5	36	M	4.96	EO	4	IIB	7	N.A.	None
6	46	F	0.01	EO	12	IIB	4	Thymic hyperplasia	PB
7	29	M	−0.13	EO	84	IIB	4	Thymic hyperplasia	PB
8	82	M	0.62	LO	36	IIA	3	None	PB
9	34	F	4.22	EO	60	I	8	None	PB
10	28	M	3.84	EO	2	IIB	3	None	None
11	3.7	F	0.1	EO	1	I	5	N.A.	None
12	55	F	4.22	LO	24	IIA	6	N.A.	PB
13	38	F	0.05	EO	4	I	7	None	None
14	57	M	3.91	LO	6	IIA	3	None	None
15	48	M	2.63	EO	24	I	3	Thymic hyperplasia	PB
16	44	F	3.01	EO	2	I	3	Thymic hyperplasia	PB
17	50	M	1.2	LO	9	I	3	None	None
18	41	M	7.56	EO	1	IIB	3	None	None
19	30	F	0.8	EO	24	I	3	None	PB
20	54	F	−0.1	LO	3	I	12	None	None
21	34	M	2.46	EO	3	IIIA	3	Thymoma	None
22	41	F	2.92	EO	14	I	3	None	PB
23	38	M	3.95	EO	2.5	I	6	None	PB
24	54	F	3.84	LO	36	IV	6	Thymoma	PB
25	27	M	4.96	EO	240	I	3	None	None
26	31	F	0.62	EO	24	I	1	None	None
27	36	F	0.13	EO	2	I	4	Thymoma	None
28	54	F	4.8	LO	72	IIB	2	None	PB
29	35	F	0.96	EO	6	I	2	N.A.	None
30	50	F	1.05	EO	96	I	9	Thymic hyperplasia	PB
31	48	M	1.96	EO	36	IIB	2	None	PB
32	14	F	2.63	EO	2	I	1	None	None
33	21	M	3.01	EO	210	I	2	Thymic hyperplasia	PB
34	67	F	1.3	LO	24	I	2	None	PB
35	65	F	5.74	LO	50	IIA	6	None	PB
36	55	F	2.92	LO	14	IIB	4	None	PB
37	25	F	2.25	EO	24	I	2	None	PB
38	46	F	3.39	EO	8	I	2	N.A.	None
39	24	M	4.64	EO	1	I	1	None	None
40	70	M	3.01	LO	1	IIA	4	None	None
41	14	F	7.88	EO	0.1	I	3	None	None

M, male; F, female; EO, early onset; LO, late onset; N.A., not available; PB, pyridostigmine bromide.